Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study



Status:Completed
Conditions:Restless Leg Syndrome, Neurology
Therapuetic Areas:Neurology, Rheumatology
Healthy:No
Age Range:18 - Any
Updated:11/30/2013
Start Date:June 2012
End Date:August 2014
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)


Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently
approved in the United States for the treatment of adults with moderate-to-severe primary
Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy,
tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already
approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to
severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a
condition of the approval of HORIZANT tablets (NDA 022399).


This is a Phase IV randomized, double-blind, placebo-controlled, fixed-dose, parallel group
study to assess the efficacy, tolerability, and safety of 3 doses of GEn (600, 450, and 300
mg/day) compared with placebo in the treatment of subjects with moderate-to-severe primary
RLS.

The study will include 9 visits over approximately 14 weeks for eligible subjects including
a 1-week Screening Period, a 12-week Treatment Period, and a 1 week Follow up Period.
Screening will occur within 1 week of the first scheduled dose of study medication. The
total duration of the study, from the first subject enrolled to the last subject completed
will be approximately 2 years.

Eligible subjects (at least 18 years of age) must have:

- a diagnosis of RLS according to the IRLSSG Diagnostic Criteria

- a history of RLS symptoms for at least 15 nights in the prior month or, if on
treatment, this frequency of symptoms before treatment was started

- documented RLS symptoms for at least 4 of the 7 consecutive evenings/nights during the
Screening Period, and a total RLS severity score of at least 15 on the International
Restless Legs Syndrome (IRLS) Rating Scale at the screening and baseline visits

Approximately 498 subjects will be enrolled, randomly assigned to treatment groups, and
receive study medication once daily for 12 weeks. Subjects will be randomly assigned to
receive 1 of the 4 following treatment groups in a ratio of 1:1:1:1:

- GEn 600 mg/day

- GEn 450 mg/day

- GEn 300 mg/day

- Matching placebo Subjects will be instructed to take their study medication once daily
with food in the evening at approximately 5 PM. Each tablet must be swallowed whole and
not divided, crushed, or chewed.

Each subject, regardless of treatment assignment, will take 3 tablets of study medication (1
tablet from Bottle A, 1 tablet from Bottle B, and 1 tablet from Bottle C) once daily
continuing through the end of the Treatment Period (Week 12). Subjects will return to the
study site for a follow-up visit (Visit 9, Week 13) approximately 1 week after the last dose
of study medication.

Each subject's participation in the study will be approximately 14 weeks unless they
withdraw early from the study. For subjects who complete the study, Visit 9 (which can occur
between Day 86 and 92) will be considered their end-of-study visit.

Inclusion Criteria:

- Men or women 18 years of age or older

- History of RLS symptoms for at least 15 nights/month

- Documented RLS symptoms, using the 7-day RLS Symptom Record, for at least 4 of the 7
consecutive evenings/nights during the night

- Total RLS severity score of 15 or greater on the International RLS (IRLS) Rating
Scale at Visit 1 and at Visit 2

- Discontinuation of dopamine agonists and/or gabapentin , or other treatments for RLS
(e.g. opioids, benzodiazepines) at least 2 weeks prior to Baseline

- If taking any prescription medication, therapy must have been stabilized for at least
3 months prior to Screening with no anticipated changes for the duration of the study

- Female subjects are eligible if of non-childbearing potential or not lactating, has a
negative pregnancy, and agrees to use a highly effective method for avoiding
pregnancy

- Body mass index of 34 or below

- Estimated creatinine clearance of ≥60 mL/min

- Provides written consent in accordance with all applicable regulatory requirements

Exclusion Criteria:

- History of a sleep disorder that may affect the assessment of RLS

- History of RLS symptom augmentation or end-of-dose rebound with previous dopamine
agonist treatment

- Neurologic disease or movement disorder

- Other medical conditions or drug therapy that could affect RLS efficacy assessments
or may present a safety concern

- Have clinically significant or unstable medical conditions

- Have active suicidal plan/intent or has had active suicidal thoughts in the past 6
months; has a history of suicide attempt
We found this trial at
24
sites
Charleston, South Carolina 29425
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Anaheim, California 92807
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Aurora, Colorado 80010
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bethesda, Maryland 20892
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Glendale, Arizona 85304
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Grand Island, Nebraska 68803
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
Grand Rapids, Michigan 49546
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Jacksonville, Florida 32207
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37916
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Las Vegas, Nevada 89102
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Providence, Rhode Island 02903
?
mi
from
Providence, RI
Click here to add this to my saved trials
Richmond, Virginia 23298
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Roswell, Georgia 30076
?
mi
from
Roswell, GA
Click here to add this to my saved trials
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Weatherford, Oklahoma 73096
?
mi
from
Weatherford, OK
Click here to add this to my saved trials
Westwood, Kansas 66205
?
mi
from
Westwood, KS
Click here to add this to my saved trials